Forest/Lipha Campral
Executive Summary
FDA approves Campral (acamprosate) July 29 for the treatment of "alcohol dependent individuals seeking to continue to remain alcohol-free after they have stopped drinking." Campral should be used as one part of a comprehensive alcoholism management program that includes "psychosocial support," FDA says in a July 29 "Talk Paper." Forest will launch the drug in the U.S. near the end of the year...
You may also be interested in...
Campral Clears FDA For Alcohol Dependence: Renal Study Part Of Phase IV
Merck KGaA subsidiary Lipha will determine appropriate Campral dosing in patients with severe renal impairment as a postmarketing commitment following FDA approval of the alcoholism therapy
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.